PUBLISHER: IMARC | PRODUCT CODE: 1722427
PUBLISHER: IMARC | PRODUCT CODE: 1722427
The global non-PVC IV bags market size reached USD 1.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.3 Billion by 2033, exhibiting a growth rate (CAGR) of 5.8% during 2025-2033.
Non-polyvinyl chloride (non-PVC) intravenous (IV) bags are manufactured using polypropylene, polyethylene, copolyester-ether, and ethylene-vinyl acetate films. They are specifically designed for packaging rehydration solutions and storing certain antibiotics and analgesics for hospital and veterinary usage. Moreover, they can be extensively utilized in cold storage without inhibiting the quality and shelf-life of the stored items. Unlike PVC IV bags that often face drug and container interaction problems, these bags provide improved safety, lowered risks of contamination and enhanced convenience of usage. As a result, non-PVC IV bags find extensive applications in parenteral nutrition, oncology, chemotherapy, and targeted drug deliveries.
The market is primarily driven by the rising incidences of hospital-acquired infections (HAIs) among the masses. Coupled with the increasing influx of patients requiring intravenous antibiotics across healthcare facilities, this has provided a boost to the uptake of non-PVC IV bags. Also, the widespread adoption of single-chambered non-PVC IV bags in IV drips and other mixtures due to their convenience of management, transportation, and disposal is significantly contributing to the product sales. In addition to this, the growing number of point-of-care (POC) facilities across the globe and the preference for home care setups, especially for the geriatric population, are favorably impacting the market growth. The market is further driven by the escalating popularity of IV bags made up of ethylene-vinyl acetate (EVA). Since these bags offer excellent adhesion to non-porous substrates at an affordable price point, they are widely utilized by healthcare professionals on the global level. Some of the other factors creating a positive outlook for the market include the augmenting demand for biologically inert medical supplies, considerable developments in the healthcare infrastructure and extensive research and development (R&D) activities.
The competitive landscape of the industry has also been examined along with the profiles of the key players being B. Braun Melsungen AG, Baxter International Inc., Becton Dickinson and Company, Fresenius SE & Co. KGaA, JW Life Science Co. Ltd., Kraton Corporation (DL Chemical Co. Ltd.), Medline Industries LP, Persico S.p.a., Sealed Air Corporation and Sippex IV bags.